CYP2C19*2 or *3 and PON-1 polymorphisms considerably diminished the platelet response to clopidogrel while the former elevates the risk of MACE in Coronary Heart Disease (CHD) patients after PCI (42). The gene discussed is CYP2C19; the disease is coronary artery disorder.